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with at least 1 prescription medication. PIP was deﬁ ned as having a prescription claim
for at least one inappropriate medication. RESULTS: A total of 23,662 elderly in the
cohort (25.8%) had at least one PIP. Of these, 14.1% received prescriptions for 2 
medications of concern, and 2.0% for 3 or more. Using the expert panel’s categories,
59.2% of the elderly receiving PIP had prescriptions for drugs that should always be 
avoided, 33.9% for rarely appropriate drugs, and 19.1% for drugs that have some
indications but are often misused. NSAIDs (35.7% of subjects) were the most fre-
quently occurring PIP, followed by ticlopidine (17.6%), doxazosin (15.5%) and amio-
darone (13.6%). Female, older age, overall number of drugs prescribed, greater 
number of chronic conditions were factors associated with greater odds of receiving 
PIP. CONCLUSIONS: Via the developed criteria, the study corroborates that PIP 
among elderly outpatients is a substantial issue in Parma LHU, Italy. Knowledge of 
the prevalence of PIP and associated factors should gear efforts to develop strategies
to reduce PIP in outpatient settings in Italy.
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OBJECTIVES: We sought to 1) estimate the occurrence of polypharmacy, 2) deﬁ ne 
characteristics of patients most at risk for polypharmacy, and 3) characterize drug
classes most commonly involved in polypharmacy in elderly patients in the Local
Health Unit (LHU) of Parma, Italy. METHODS: We conducted a retrospective analysis 
of the 2007 Parma LHU automated outpatient prescriptions database. A total of 
97,043 patients q65 years (94.2% of the cohort) who had at least one prescription 
medication were included in the study. Using the World Health Organization’s Deﬁ ned
Daily Dose (DDD) to determine the duration of treatment for a given drug, we deﬁ ned
a polypharmacy episode as overlapping treatment with ﬁ ve or more drugs occurring 
at least one day during the study period. RESULTS: A total of 37,789 elderly in the 
population (38.9%) were exposed to at least one polypharmacy episode. The preva-
lence of polypharmacy substantially increased with age; 45.5% and 46.8% of indi-
viduals, respectively, in the 75–84 age group and 85 years and older were exposed to
polypharmacy. For the exposed to polypharmacy, the median number of days of 
exposure was 55 and 14.8% were exposed for more than 200 days. Compared to the 
unexposed elderly, subjects exposed to polypharmacy were older, were prevalently 
male, and had a greater number of chronic conditions. Cardiovascular, gastrointestinal 
and metabolism, and blood medications were most commonly involved in polyphar-
macy. CONCLUSIONS: Polypharmacy is widespread among the elderly. LHU manag-
ers should develop educational activities to make general practitioners aware of the
magnitude of polypharmacy phenomenon among their elderly patients. In addition,
LHU and clinicians should jointly identify strategies to closely monitoring elderly 
patients more likely to be exposed to polypharmacy.
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OBJECTIVES: 1) To describe how many Medicare Part D enrolled seniors without 
Low Income Subsidy (LIS) reached the doughnut hole (coverage gap) in 2007, when 
they reached the doughnut hole, and how long they stayed in it. 2) To compare drug 
use and expenditures between Part D enrolled seniors without LIS who reached the
doughnut hole and those who did not. METHODS: A retrospective, descriptive study 
design was used for the study. Data were extracted from the claims database of a 
supermarket pharmacy chain in Virginia. Study population was identiﬁ ed using the 
following selection criteria: age 65 as of January 1, 2007, at least one prescription ﬁ ll 
at the participating pharmacy chain between January 1 to December 31, 2007, enroll-
ment in a Medicare Part D plan throughout 2007, and no LIS in 2007. Whether or 
not a person had reached doughnut hole was determined at the patient-level for each
month based on the cumulative total drug spending in that month. Descriptive statis-
tics were used for the ﬁ rst objective. T-tests were used to compare seniors who reached
the doughnut hole and those that did not. RESULTS: Just below 14% of Part D 
enrolled seniors without LIS reached the doughnut hole in 2007, of which, about 15% 
reached the catastrophic coverage. Part D enrolled seniors who reached the doughnut 
hole had signiﬁ cantly higher drug use, expenditures, and proportion of brand medica-
tion ﬁ lls as compared to seniors that did not reach the doughnut hole. CONCLU-
SIONS: A relatively low proportion, but vulnerable population of Part D enrolled
seniors without LIS reached the doughnut hole in 2007. Seniors who reached the
doughnut hole had a signiﬁ cantly lower proportion of generic medication ﬁ lls, sug-
gesting that there is an opportunity to delay or even avoid the doughnut hole for some
seniors by switching to lower-cost generics.
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OBJECTIVES: To measure the difference in out-of-pocket and total costs among
subjects receiving different quantities of the same prescription drug used to treat a
chronic condition and to examine patient and health system characteristics associated
with the use of a three-month supply. METHODS: We pooled data from the 2000–
2005 Medical Expenditure Panel Survey, a nationally representative survey of the 
U.S. non-institutionalized civilian population, to compare prescription drug expendi-
tures for medicines dispensed as both three-month and one-month supplies. Mean 
monthly out-of-pocket and total costs were measured as the main outcomes and 
expressed in 2005 dollars. Logistic regression was used to model correlates associated 
with three-month use. RESULTS: Forty-four percent of prescriptions examined 
were dispensed as three-month supplies. The average adjusted monthly total and out-
of-pocket costs for a 1-month supply were $42.72 (95% conﬁ dence interval [CI]
$42.01–$43.42) and $20.44 (CI $19.99–$20.89) while the corresponding monthly
costs for a 3-month supply were $37.95 (CI $37.26–$38.64) and $15.10 (CI $14.68–
$15.53), representing a 29% decrease in out-of-pocket costs and a 18% decrease in
total prescription costs through the use of a three-month rather than a one-month 
supply. Eighty percent of the people saved some positive amount from a three-month 
supply and there was considerable variation in the amount saved. There were no 
marked differences in the characteristics of individuals using 3-month vs. 1-month 
supplies. CONCLUSIONS: Although such opportunities are not universally available,
these ﬁ ndings quantify the cost-savings that patients in the United States can achieve 
through ﬁ lling larger quantities of a prescription for a chronic condition. Many 
patients are burdened by prescription costs, and patients, providers, and policy-makers
may attempt to reduce these costs by substituting three-month for one-month supplies
of medicines.
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OBJECTIVES: The Part D drug beneﬁ t, implemented on January 1, 2006, reﬂ ected a 
signiﬁ cant change in prescription drug coverage for over six million beneﬁ ciaries
dually eligible for Medicare and Medicaid. We examined the effect of Part D on dual
eligibles’ prescription drug usage, out-of-pocket costs, and total drug expenditures. 
METHODS: We selected a random sample of unique pharmacy customers of a 
national retail pharmacy chain who ﬁ lled at least one prescription during both 2005 
and 2006. For each subject, we obtained claims for every prescription ﬁ lled between 
January 1, 2005 and April 31, 2007. We used generalized estimating equations (GEE) 
to compare the experience of a “treatment” group (dual-eligibles between 65–78 years 
of age on January 1, 2005) with that of a “control” group (near-elderly Medicaid 
patients between 60–63 years of age who had continuous drug coverage through 
Medicaid pre- and post-Part D) during the ﬁ rst 18 months after Part D implementa-
tion. RESULTS: Expenditures for the treatment and control groups tracked each other
closely in the pre-Part D period. Immediately following the implementation of Part D,
expenditures for both groups decreased and then leveled off. There were no signiﬁ cant
changes in trends in dual-eligibles’ out-of-pocket expenditures, total monthly expen-
ditures, pill-days, or total number of prescriptions due to Part-D. CONCLUSIONS:
Part D represented a policy change of enormous proportions, and there was consider-
able concern about the impact of the transition on dual eligibles. Many of these chal-
lenges were anticipated, and efforts by numerous stakeholders were made to address 
those that weren’t anticipated. We ﬁ nd no evidence that Part D adversely affected
pharmaceutical utilization or out-of-pocket expenditures for dual eligibles during the 
transition period, nor during the 18 months subsequent to Part D implementation.
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OBJECTIVES: The preparation of intravenous compounds usually involves the use of 
high cost drugs, hence it is important to optimize the available resources in order to 
sustain the service without detriment in the quality offered to patients. The objective
of this study was to quantify and document the savings reached through waste reduc-
tion and the reuse of intravenous compounds returned to the mix center unaltered,
maintaining their sterility, in compliance with quality requirements, within their life
spam, and as long as the medical prescriptions were equivalents. METHODS: During
2006, through the daily registration of preparations in the compound center of the 
CMNO, a monthly analysis was carried out, considering the number of intravenous 
compounds prepared and returned, as well as the reason for this latter action; their 
ﬁ nal destination; and the percentage of preparation remnants to be disposed of. The 
data collected was tabulated and charted to determine monthly averages of each 
group, with the objective of identifying trends, if any. RESULTS: During the year a 
total of 25,154 intravenous compounds were prepared, of which 404 (1.6%) were 
returned, 214 (0.85%) of these were reused and 190 (0.76%) were disposed of. On 
a monthly average from total compounds prepared: 1.64% are returned, 0.87% are 
reused and 0.77% are disposed of. CONCLUSIONS: There are two ways to maximize 
the economy in the use of resources and medication: the ﬁ rst is to use the content of 
each drug vial to its maximum, thus reducing remnants to about 1% a month; the
second is to optimize the intravenous compound units, in the compound center, that 
for different reasons are not administered to patients, having only to dispose of 0.76%
of compounds prepared.
